Q1 2026 saw strategic advances, including a 7.3 MSEK share issue, new patent filings, and positive phase III survival data for Platin-DRP® in NSCLC. Financials improved with higher liquidity and equity, while the outlook remains strong for precision oncology solutions.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.